Loading
A phase 3 trial of Furmonertinib, Carboplatin, Cisplatin, Pemetrexed and Osimertinib in non-small-cell lung cancer, run by Allist Pharmaceuticals, Inc., now recruiting.
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases is a phase 3 interventional study registered as NCT06970639 by Allist Pharmaceuticals, Inc., with 380 participants planned, started 2024-09-26 and due to reach its primary completion in 2029-03. Interventions recorded: Furmonertinib Mesilate Tablets, Carboplatin Injection, Cisplatin for injection, Pemetrexed Disodium for Injection and Osimertinib Mesylate Tablets.
Shares Shanghai Allist Pharmaceuticals, Furmonertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors and the tag pipeline.
Shares Shanghai Allist Pharmaceuticals, Furmonertinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Osimertinib, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin and the tag pipeline.
Shares Osimertinib, Pemetrexed, Cisplatin, Carboplatin and the tag pipeline.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin, Carboplatin and the tag pipeline.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Small-molecule kinase inhibitors and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-molecule kinase inhibitors and the tag pipeline.